TCGA-66-2792-01A-01R-0980-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 58
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.620
- G2M_CHECKPOINT+0.600
- MYC_TARGETS_V1+0.490
- MITOTIC_SPINDLE+0.420
- UNFOLDED_PROTEIN_RESPONSE+0.420
- MTORC1_SIGNALING+0.410
- DNA_REPAIR+0.400
- MYC_TARGETS_V2+0.400
- HEDGEHOG_SIGNALING+0.390
- PROTEIN_SECRETION+0.330
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.380
- INTERFERON_ALPHA_RESPONSE-0.370
- ANGIOGENESIS-0.360
- INTERFERON_GAMMA_RESPONSE-0.340
- COAGULATION-0.330
- KRAS_SIGNALING_DN-0.300
- COMPLEMENT-0.280
- INFLAMMATORY_RESPONSE-0.260
- IL6_JAK_STAT3_SIGNALING-0.250
- TNFA_SIGNALING_VIA_NFKB-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-98-A538-01A-11R-A262-07 | — | cohortSQ1 | 0.904 |
| 2 | SRR8392891 | — | cohortSQ2 | 0.886 |
| 3 | 800E78BA-08BE-463B-ABBA-45255B48362B | — | — | 0.885 |
| 4 | TCGA-68-7755-01A-11R-2125-07 | — | cohortSQ2 | 0.879 |
| 5 | TCGA-77-8009-01A-11R-2187-07 | — | cohortSQ2 | 0.877 |
| 6 | ERR2598051 | fetal | fetal | 0.873 |
| 7 | TCGA-21-1072-01A-01R-0692-07 | — | cohortSQ2 | 0.871 |
| 8 | EE4F9349-F750-4471-BFE7-7230784569E1 | — | — | 0.868 |
| 9 | MNG753 | — | — | 0.866 |
| 10 | E3A67B7B-7427-4C11-912B-166451072767 | — | — | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.620 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.420 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.420 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.390 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.260 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.140 | Inavolisib | — uncovered |